New drug combo aims to shrink Hard-to-Treat cancers

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Willing and able to sign the study consent form and take part in all required study visits, tests, and procedures. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. * Have a locally advanced or metastatic cancer that cannot be removed with surgery and has gotten worse despite treatment. * Cancer can be measured on scans, such as CT or MRI. * Willing to have tumor biopsies, meaning small samples of your tumor will be collected during the study. * Heart rhythm test (ECG) shows a normal result within safe limits. * Blood test results at screening are within an acceptable and stable range. * If you are a woman, you are not able to become pregnant, or you agree not to become pregnant during the study and to use approved birth control methods. * If you are a man, you agree not to donate sperm during the study. If you have sex with a partner who could become pregnant, you agree to use approved birth control methods during the study. Exclusion Criteria: * Unable to swallow the study medication or your body cannot absorb it. * Have had a serious allergic reaction to LRK-4189 or any of its ingredients. * Have needed a fluid drainage procedure from the chest or abdomen within the past 6 weeks. * Have active cancer in the brain or spinal fluid, or brain tumors that require steroid treatment. * Currently receiving another cancer treatment. * Have an active HIV, hepatitis B, or hepatitis C infection with detectable virus levels. * Have an active infection that requires treatment through a vein (IV). * Taking certain medications that strongly interact with the study drug and cannot stop them at least 14 days before starting the study. * Pregnant or breastfeeding or planning to become pregnant or father a child during the study. * Cannot safely receive the standard chemotherapy that would be used with this study.